Join the Vemlidy group to help and get support from people like you.
Vemlidy News
Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease
TUESDAY, May 20, 2025 – Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), which treat HIV and hepatitis B and inhibit inflammasome activation, is associated with a significantly lower...
Key HIV Care Teams Let Go, Putting Mothers and Children at Risk
WEDNESDAY, April 9, 2025 – The Trump administration has let go of the last remaining U.S. health officials who oversaw HIV care for more than 1.1 million mothers and children in low-income...
FDA Expands Indication for Gilead's Vemlidy (tenofovir alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
March 28, 2024 – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug...
U.S. Food and Drug Administration Approves Vemlidy (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Approval Expands on Previous FDA Approval of Vemlidy in Adults Living With This Chronic Liver Disease Efficacy and Safety of Once-Daily Vemlidy Demonstrated in Individuals 12 Years of Age and Older ...
FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...
FDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir...